Epic and LabCorp’s Covance have agreed to extend their partnership to provide circulating tumor cell (CTC) technology and oncology clinical trial support in Asia.
Juniper Pharma Services has won a contract to manufacture ‘sono-sensitive particles’ used to aid delivery of cancer drugs into solid tumours for OxSonics.
Roche’s Ventana Medical Systems will help Astellas find patients likely to be helped by its candidate cancer drug ASP5878 in a deal that could yield a commercial companion diagnostic.
Preclinical CRO Crown is acquiring all of Molecular Response’s existing PDX (patient-derived xenograft) models as well as 8,000 viable human tumors for model development.
Researchers from the Oncology Department of Tianjin Medical University Cancer Hospital in China recently published a study in Advanced Functional Materials announcing the creation of a new nano-carrier for pancreatic cancer treatments.
A magnetic pulse technology that can align and push nanoparticles to points distant to magnet surfaces could finally make magnets attractive for deep tissue drug delivery according to researchers.
Sweden is an expert in high-tech trials but stalls in the recruitment phase, says the academic trying to change all that with a database of biomarkers matching patients to studies.
A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in cannabis in reducing tumour size, which also may lead to the development of a synthetic THC equivalent, scientists say.
Karyopharm Therapeutics has selected CRO Clinipace to help discover first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
As biopharma companies look to develop cancer therapies more quickly, some are turning to CROs with the hopes of using surrogate endpoints to expedite US FDA approval.
CRO Covance is teaming up with M2Gen’s cancer-focused database to increase its ability to match more patients in oncology trials based on their tumour profiles.
Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.
UK-based Endeavour Specialty Chemicals has launched a range of thioamide intermediates, citing growing evidence of their potential role in development of new cancer treatments.
PsiOxus Therapeutics has predicted growing demand for oncolytic vaccines, citing recent industry acquisitions as evidence of the need for novel treatments for cancer.
Quintiles and Dako, a Danish-based cancer diagnostics firm, are teaming up to help speed development of personalised medicine by collaborating on the co-development of targeted oncology therapies and diagnostics.
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
US CRO Quintiles expands PI3K assay offering, predicting increased drug industry demand for expertise in key survival pathway in era of personalised cancer treatments.
France-based CRO Cellvax has moved to a new laboratory to provide clients with large animal services and new technical platforms, such as scintigraphy, histological analysis and biomarkers.
Quintiles Transnational has boosted its array of services for companies developing cancer drugs via the purchase of Illinois, US-based firm Targeted Molecular Diagnostics.
Charles River Laboratories has agreed to buy US-based drug discovery imaging expert Molecular Imaging Research, Inc. (MIR) for approximately $12.5m (€8.8m) in cash.
Advalytix’ AmpliGrid technology is playing a key role in enabling researchers to discover how just a single cell can lay a huge role in complex biological systems.
US-based Delcath Systems has achieved positive results in treating
diffuse liver cancer using its percutaneous hepatic perfusion (PHP)
delivery system.
The creation of a new 'super cell' that can stand firm against one
of the newest types of cancer therapy could shed new light on how
to treat patients if they become resistant to these drugs.
Gene expression analysis expert Exiqon is to pay up to $45m
(€30.7m) for diagnostics company Oncotech as a first step towards
becoming a world leading miRNA diagnostic manufacturer.
Bristol-Myers Squibb (BMS) will pay up to $490m (€348m) for Adnexus
Therapeutics, as it continues its transformation into a
biopharmaceutical company and strengthens its oncology pipeline.
UK firm Protherics has inked a deal with a Korean partner allowing
the company to make use of its temperature sensitive sustained
release drug delivery system.
Cell Therapeutics has acquired oncology expert Systems Medicine
(SMi) in a deal worth up to $35m (€25.5m) that includes
worldwide rights to brostallicin that belongs to a new class of
cancer drugs.
Oxigene's potentially first-in-class cancer drug is showing
promising clinical results and could rival a drug Novartis'
recently spent nearly a billion dollars on.
Bacterially derived nanocells that can deliver chemotherapeutic
drugs directly to cancer cells without the shortcomings of
liposomal or viral carriers could be in clinical trials by the end
of this year, an Australian biotechnology...
Pro-Pharmaceuticals is preparing to submit a New Drug Application
(NDA) for its lead product candidate, Davanat, as a functional
excipient that promises to hike the efficacy and cut the side
effects of cancer drugs.
PRA International has entered into an alliance with US Oncology
Research, designed to accelerate the clinical development of new
cancer treatments in the US.
Forbes has highlighted the important role of nanotechnology in
driving forward the pharmaceutical industry with three of their top
five nanotech breakthroughs in 2006 having biological applications.
Ciphergen has hired contract research organization (CRO)
PrecisionMed to help it with upcoming clinical trials for its
experimental ovarian cancer tests.
Genentech and Inotek have entered into a strategic alliance in
which they will concentrate on the discovery, development and
commercialisation of PARP inhibitors for cancer - a class of drug
that has demonstrated high efficacy in...
Locus Pharmaceuticals is to initiate Phase I trials of a novel
anticancer drug that could prove effective against drug resistant
tumours after the small molecule cleared the 30-day review period
by the FDA for its Investigational...
Researchers have developed a new nanocarrier system for the
delivery of drugs which contains iron and so can be directed by a
magnetic field to specific areas of the body, a technology which
could prove invaluable in the treatment...
A new laboratory test that identifies patients who benefit most
from targeted cancer drugs was the talk of the annual meeting of
the American Society of Clinical Oncology (ASCO) as the test's
accuracy is sure to save hundreds...
Cambrex Bio Science has been given a contract to manufacture
Geron's GRNVAC1 telomerase vaccine for use in clinical trials and
will now transfer production to its Walkersville, Maryland
facility.
CuraGen and TopoTarget have announced preliminary data suggesting
its small molecule candidate may have potential anti-tumour
activity against haematologic cancer.
Biovest International used the Cancer Research Institute's recent
meeting to debut its newest cell culture instrument, the
AutovaxID-C, which represents an advance in personalised medicine,
reducing the possibility of cross contamination,...
Researchers have identified two proteins involved in the process
that controls plant growth, which may help explain why human cells
reject chemotherapy drugs and could form a basis for new oncology
drugs.
